1. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-161.
2. Hutton B, Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 2004;80:1461-1468.
3. Hansen DL, Astrup A, Toubro S, Finer N, Kopelman P, Hilsted J, et al. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. International Journal of Obesity 2004;28:378-383.
4. One-Year Outcome of a Combination of Weight Loss Therapies for Subjects With Type 2 Diabetes, A randomized trial. Diabetes Care 2003;26:2505-2511.
5. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003;11:1116-1123.
6. Bray GA, Ryan DH. In: Bray GA, Bouchard C, editor. Sympathomimetic and serotoninergic drugs used to treat obesity. Handbook of obesity, Clinical applications 2004;2nd ed. Marcel Dekker, Inc.: USA. 201-238.
7. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M. OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. International Journal of Obesity 2004;28:1399-1410.
8. Anderson JW, Greenway FL, Fujioka K, Gadde KM, Mc-Kenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res 2002;10:633-641.
9. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003;289:1820-1825.
10. Goldstein DJ, Rampey AH Jr, Enas GG, Potvin JH, Fludzinski LA, Levine LR. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord 1994;18:129-135.
11. Norris S, Zhang X, Avenell A, Gregg E, Schmid Ch, Lau J. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;25:CD004096.
12. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. RIO-Europe Study Group. Effects of the cannabi-oid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from RIO-Europe study. Lancet 2005;365:1389-1389.